Current Evolutions in Axillary Management
Breast Care 2022;17:1 –2 (Source: Breast Care)
Source: Breast Care - December 5, 2022 Category: Cancer & Oncology Source Type: research
Effectiveness of Peer Support on Quality of Life and Anxiety in Breast Cancer Patients: A Systematic Review and Meta-Analysis
Conclusion: Peer support intervention has the potential to effectively improve psychosocial adaptations in breast cancer patients. Future studies with a robust design and larger sample size are needed to investigate the potential factors associated with the beneficial effects of peer support. (Source: Breast Care)
Source: Breast Care - November 25, 2022 Category: Cancer & Oncology Source Type: research
Evolution of HER2 Targeting in Metastatic Breast Cancer
Breast Care (Source: Breast Care)
Source: Breast Care - November 10, 2022 Category: Cancer & Oncology Source Type: research
Evolution of HER2 Targeting in Metastatic Breast Cancer
(Source: Breast Care)
Source: Breast Care - November 10, 2022 Category: Cancer & Oncology Source Type: research
Evolution of her2-targeting in metastatic breast cancer
none (Source: Breast Care)
Source: Breast Care - November 10, 2022 Category: Cancer & Oncology Source Type: research
Impact of the Latest Clinical Data among Patients with Breast Cancer in Low- and Middle-Income Countries
Breast Care (Source: Breast Care)
Source: Breast Care - November 8, 2022 Category: Cancer & Oncology Source Type: research
Impact of the latest clinical data among patients with breast cancer in low- and middle-income countries
not applicable (Source: Breast Care)
Source: Breast Care - November 8, 2022 Category: Cancer & Oncology Source Type: research
Clinical Importance of PGRMC1 in Hormone Responsive Breast Cancer
Background: For the development of PGRMC1, a multifunctional receptor belonging to membrane-associated progesterone receptor proteins (MAPR) family, as possible predictive marker for increased hormone-dependent breast cancer (BC) risk, a systematic research program has been performed, starting with different BC cells, continued with animal studies and finally with clinical studies with BC patients.Summary: In vitro studies showed dose- and time-dependent BC cell proliferations with all available synthetic progestogens (not with progesterone), but mostly significant only in the presence of PGRMC1. Different animal (xenograf...
Source: Breast Care - November 8, 2022 Category: Cancer & Oncology Source Type: research
Clinical importance of PGRMC1 in hormone responsive breast cancer
Background:
For the development of PGRMC1, a multifunctional receptor belonging to membrane-associated progesterone receptor proteins (MAPR) family, as possible predictive marker for increased hormone-dependent breast cancer risk, a systematic research program has been performed, starting with different breast cancer (BC) cells, continued with animal studies and finally clinical studies with BC-patients.
Summary:
In-vitro studies showed dose- and time-dependent BC-cell proliferations with all available synthetic progestogens (not with progesterone), but mostly significant only in presence of PGRMC1. Different animal(xe...
Source: Breast Care - November 8, 2022 Category: Cancer & Oncology Source Type: research
CDK4/6 inhibitors in advanced HR+/HER2- breast cancer – a multicenter real world data analysis
Conclusion:
Our RWD analysis on CDK4/6i treatment in Germa ny supports data from RCTs regarding both treatment efficacy and safety of CDK4/6i for treatment of patients with HR+/HER2- ABC. In comparison to data from the pivotal RCTs, median PFS was lower but within the expected range for RWD which could result from inclusion of patients with more advanced di sease (i.e., higher therapy lines) to our dataset. (Source: Breast Care)
Source: Breast Care - November 8, 2022 Category: Cancer & Oncology Source Type: research
Prediction of Cardiac Toxicity by Measurement of Coronary Artery Calcium Scoring Method Using Chest Computed Tomography in Early Breast Cancer Patients Treated with Trastuzumab
Conclusion: Our findings suggest that the CAC score is a significant predictor of cardiac toxicity following trastuzumab treatment in HER2-positive breast cancer. Therefore, CAC measurement could reduce cardiac toxicity by distinguishing patients at high risk for trastuzumab.Breast Care (Source: Breast Care)
Source: Breast Care - November 3, 2022 Category: Cancer & Oncology Source Type: research
Prediction of cardiac toxicity by measurement of coronary artery calcium scoring method using chest computed tomography in early breast cancer patients treated with trastuzumab
Conclusion: Our findings suggest that the CAC score is a significant predictor of cardiac toxicity following trastuzumab treatment in HER2-positive breast cancer. Therefore, CAC measurement could reduce cardiac toxicity by distinguishing patients at high risk for trastuzumab. (Source: Breast Care)
Source: Breast Care - November 3, 2022 Category: Cancer & Oncology Source Type: research
